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Dosage analysis of the 7q11.23 Williams region 
identifies BAZ1B as a major human gene  
patterning the modern human face and  
underlying self-domestication
Matteo Zanella1,2*†, Alessandro Vitriolo1,2*, Alejandro Andirko3,4, Pedro Tiago Martins3,4, 
Stefanie Sturm3,4, Thomas O’Rourke3,4, Magdalena Laugsch5,6,7, Natascia Malerba8, 
Adrianos Skaros1,2, Sebastiano Trattaro1,2, Pierre-Luc Germain1,2,9, Marija Mihailovic1,2, 
Giuseppe Merla8, Alvaro Rada-Iglesias5,10,11, Cedric Boeckx3,4,12, Giuseppe Testa1,2,13‡
We undertook a functional dissection of chromatin remodeler BAZ1B in neural crest (NC) stem cells (NCSCs) from 
a uniquely informative cohort of typical and atypical patients harboring 7q11.23 copy number variants. Our 
results reveal a key contribution of BAZ1B to NCSC in vitro induction and migration, coupled with a crucial 
involvement in NC-specific transcriptional circuits and distal regulation. By intersecting our experimental data 
with new paleogenetic analyses comparing modern and archaic humans, we found a modern-specific enrichment 
for regulatory changes both in BAZ1B and its experimentally defined downstream targets, thereby providing the 
first empirical validation of the human self-domestication hypothesis and positioning BAZ1B as a master regulator 
of the modern human face. In so doing, we provide experimental evidence that the craniofacial and cognitive/
behavioral phenotypes caused by alterations of the Williams-Beuren syndrome critical region can serve as a powerful 
entry point into the evolution of the modern human face and prosociality.
INTRODUCTION
Anatomically modern humans (AMHs) exhibit a suite of craniofacial 
and prosocial characteristics that are reminiscent of traits distin-
guishing domesticated species from their wild counterparts (1–3). 
This has led to the formulation of a self-domestication hypothesis 
according to which modern humans (3) went through a domestica-
tion process in the course of their evolution. Recent evidence, along 
with the well-warranted distinction between domestication and 
selective breeding (4), is also extending this notion to other species 
that might have undergone a self-domestication phase, such as cats, 
dogs, and bonobos (3). Thus, as self-domestication represents a spe-
cial case of domestication, the most parsimonious hypothesis must 
posit the same core mechanisms to underlie both. For this reason, 
the self-domestication hypothesis also entails the prediction that 
key aspects of modern humans’ anatomy and cognition can be illu-
minated by studies of the so-called “domestication syndrome,” the 
core set of domestication-related traits that was recently proposed 
to result from mild neural crest (NC) deficits (5). However, both the 
neurocristopathic basis of domestication and its extension to the 
evolution of AMHs remain to be tested experimentally.
Williams-Beuren syndrome [WBS; OMIM (Online Mendelian 
Inheritance in Man) 194050] and Williams- Beuren region duplication 
syndrome (7dupASD; OMIM 609757), caused respectively by the 
hemideletion or hemiduplication of 28 genes at the 7q11.23 region 
[WBS critical region (WBSCR)], represent a paradigmatic pair of 
neurodevelopmental conditions whose NC-related craniofacial dys-
morphisms and cognitive/behavioral traits (6, 7) bear directly on 
domestication-related traits relevant for AMHs (facial reduction and 
retraction, pronounced friendliness, and reduced reactive aggres-
sion) (fig. S1A). Structural variants in WBS genes, for example in 
the case of GTF2I and its paralogs, have been shown to underlie 
stereotypical hypersociability in domestic dogs and foxes (8, 9).
Among the WBSCR genes, we focus here on the chromatin 
regulator BAZ1B (also known as Williams syndrome transcription 
factor, WSTF), on the basis of the following lines of evidence that 
implicate it in domestication-relevant craniofacial features: (i) its 
established role in NC maintenance and migration in Xenopus laevis 
and the craniofacial defects observed in knockout mice (10, 11); (ii) 
the observation that its expression is affected by domestication- 
related events in canids (12); (iii) the first formulation of the neuro-
cristopathic hypothesis of domestication, which included BAZ1B 
among the genes influencing NC development (5); (iv) the most compre-
hensive studies focusing on regions of the modern human genome 
associated with selective sweep signals compared to Neanderthals/
Denisovans (hereafter “archaics”) (13, 14), one of which specifically in-
cluded BAZ1B within the detected portions of the WBSCR; and (v) the 
thus far most detailed study systematically exploring high-frequency (HF) 
(>90%) changes in modern humans for which archaic humans carry the 
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ancestral state, which found BAZ1B enriched for mutations in modern 
humans (most of which fall in the regulatory regions of the gene) (15).
Our previous work had established the largest cohort of 7q11.23 
patient-derived induced pluripotent stem cell (iPSC) lines and 
revealed major disease-relevant transcriptional dysregulation that 
was already apparent at the pluripotent state and became further 
exacerbated upon differentiation (16). Here, we first harness this 
resource to dissect the impact of BAZ1B dosage on the NC of patients 
with WBS and 7dupASD, both in terms of function (i.e., NC migration 
and induction) and of transcriptional and chromatin dysregulation, 
thereby defining the BAZ1B dosage–dependent circuits controlling 
the NC. Next, we apply these experimentally determined BAZ1B- 
dependent circuits underlying craniofacial morphogenesis to inter-
rogate the evidence from paleogenomic analyses, which were thus 
far only of a correlative nature. We find major convergence between 
the BAZ1B control and the genes harboring regulatory changes in 
the modern human lineage. Together, the definition of the role of 
BAZ1B dosage in craniofacial neurocristopathy and its application 
to domestication-relevant paleogenomics demonstrate a major con-
tribution of BAZ1B to the modern human face and offer experimental 
validation for the prediction at the heart of NC-based accounts of 
(self-) domestication: that the modern human face acquired its shape 
as an instance of mild neurocristopathy.
RESULTS
Establishment and validation of an extensive cohort 
of patient-specific BAZ1B-interfered NC stem cell lines
To dissect the role of BAZ1B in the craniofacial dysmorphisms that 
characterize WBS and 7dupASD, we started from our previous 
characterization of WBS patient– and 7dupASD patient–specific 
iPSC lines and differentiated derivatives (16) and selected a cohort 
of 11 NC stem cell (NCSC) lines (four from patients with WBS, 
three from patients with 7dupASD, and four from control individuals), 
which also represent the largest cohort of patient-specific NCSCs 
described so far. Given the centrality of the cranial NC for the develop-
ment of the face, we first validated the cranial identity of our NCSC 
cohort by transcriptomic profiling through a manually curated gene 
expression signature (fig. S2A), confirming their suitability for the 
study of craniofacial dysregulations. We then knocked down BAZ1B 
via RNA interference in all lines across the three genetic conditions, 
including also NCSCs derived from a particularly informative patient 
with atypical WBS (hereafter atWBS) bearing a partial deletion of 
the region that spares BAZ1B and six additional genes (Fig. 1A) 
(17). To establish a high-resolution gradient of BAZ1B dosages, we 
selected two distinct short hairpin RNA (shRNA) against BAZ1B 
(i.e., sh1 and sh2) along with a scrambled shRNA sequence (hereafter 
scr) as negative control, for a total of 32 NCSC lines. Knockdown 
(KD) efficiency was evaluated at the RNA level by quantitative poly-
merase chain reaction (qPCR) (Fig. 1B and fig. S1C), confirming 
the attainment of the desired gradient with an overall reduction of 
about 40% for sh1 and 70% for sh2, as well as reduction at the protein 
level, as detected by Western blot (fig. S1E).
BAZ1B dosage imbalance impairs NCSC migration 
and induction
NCSCs need to migrate to reach specific target regions in the develop-
ing embryo and give rise to distinct cell types and tissues, including 
craniofacial structures that are major areas of change in human 
evolution. Since BAZ1B KD was shown to affect the migration of the 
NC in X. laevis and to promote cancer cell invasion in different lung 
cancer cell lines (10, 18), we hypothesized that the BAZ1B dosage 
imbalances entailed in the 7q11.23 syndromes could result in a 
defective regulation of NCSC migration and might underlie the 
NC-related alterations typical of patients with WBS and 7dupASD. 
To test this, we compared the migration properties of patient-specific 
BAZ1B KD NCSC lines (sh2) to their respective control NCSC line 
(scr) by the well-established wound-healing assay. The 7dupASD 
NCSC KD lines took longer to fill the wound when compared to the 
respective control lines (scr), as indicated by images taken at 8 and 
16 hours after a gap was created on the plate surface (Fig. 1C and 
fig. S1F). We instead observed an opposite behavior for the WBS 
BAZ1B KD lines, which were faster than the respective scr lines in 
closing the gap (Fig. 1C and fig. S1F). In contrast to the previous 
observations from X. laevis (10), we also observed a minor delay in 
NC induction as a consequence of BAZ1B KD (Fig. 1D and fig. S1D), 
by means of a differentiation protocol based on NC delamination 
from adherent embryoid bodies (EBs), which recapitulates the initial 
steps of NC generation (19). In particular, starting from 2 to 3 days 
after attachment of EBs, we observed a lower number of outgrowing 
cells in the KD line (Fig. 1D, days 7 and 10), coupled with an 
evidently higher cell mortality. Cells were eventually able to acquire 
the typical NC morphology, although lower differentiation efficiency 
was evident, as shown by images taken at day 12. In addition, the 
delay in NC formation was associated with a down-regulation of 
well-established critical regulators of NC migration and maintenance, 
including NR2F1, NR2F2, TFAP2A, and SOX9 (Fig. 1E). These 
results show that BAZ1B regulates the developing NC starting from 
its earliest migratory stages and that the symmetrically opposite 
7q11.23 dosages alterations prime NCSCs to symmetrically opposite 
deficits upon BAZ1B interference. In turn, the central role of the 
NC in the development of facial morphology allows relating such 
findings to the symmetrically opposite craniofacial dysmorphisms 
of the two 7q11.23 syndromes.
BAZ1B interference disrupts key NC-specific  
transcriptional circuits
Having defined the functional impact of BAZ1B dosage on NC 
function, we predicted that a main molecular readout of its dosage 
imbalances would be at the level of transcriptional regulation, given 
its critical role as transcriptional regulator in different cell and animal 
models (20–22). To test this hypothesis and gain mechanistic insights 
into the specific BAZ1B dosage–dependent downstream circuits, 
we subjected 32 interfered NCSC lines to high-coverage RNA 
sequencing (RNA-seq) analysis. As shown in fig. S2A, a manually 
curated signature from an extensive literature review (23–28) 
validated the cranial identity of our NCSC lines, while clustering by 
Pearson correlation excluded the presence of any genotype- or hairpin- 
specific expression change. Confirming our previous observations 
in the two largest cohorts of iPSC lines (29), a principal component 
analysis (PCA) corroborated the significant impact of individual 
genetic backgrounds on transcriptional variability, with most “KD 
lines” clustering with their respective control “scr line.” This was 
consistent with the narrow range of experimentally interfered 
BAZ1B dosages and pointed to a selective BAZ1B dosage–dependent 
transcriptional vulnerability (fig. S2B).
To dissect it, we thus resorted to a combination of classical pairwise 
comparative analysis, contrasting shBAZ1B-interfered NCSC lines 
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Fig. 1. BAZ1B KD impairs migration and induction of patient-specific iPSC-derived NCSCs. (A) Schematic representation of the KD strategy on our iPSC-derived NCSC 
cohort. (B) BAZ1B mRNA levels in all the interfered lines (scr, sh1, and sh2) as measured by qPCR. Data represent aggregates of samples with the same number of BAZ1B 
copies (7dup, CTL + atWBS, and WBS). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is used as a normalizer. (C) Eight- and 16-hour time points from the 
wound-healing assay analyses performed on a 7dupASD and a WBS NCSC line upon BAZ1B KD. Cells from the same line infected with the scr sh were used as references 
for the migration (n = 2). (D) Days 7, 10, and 12 of NC differentiation from embryoid bodies (EBs) of an scr-interfered iPSC line and its respective BAZ1B KD (n = 3). (E) mRNA 
levels of NC markers at day 12 of differentiation in three individual experimental replicates [bright-field images are reported in (D)]. An iPSC line is included as a negative 
control. Student’s t test was used (ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0. 0001).
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(sh1 + sh2) with their respective controls (scr), with a complementary 
regression analysis using BAZ1B expression levels as independent 
variables, subtracting the contribution of individual genetic back-
grounds. This design increases robustness and sensitivity in the identi-
fication of genes that, across multiple genetic backgrounds and target 
gene dosages, might have a different baseline (scr) across individuals 
while still being robustly dysregulated upon BAZ1B interference.
The two analyses identified a total of 448 genes with false discovery 
rate (FDR) < 0.1 (1192 with P < 0.01 and FDR < 0.25) whose tran-
scriptional levels followed BAZ1B dosage, in either a direct (202; 539 
with P < 0.01 and FDR < 0.25) or an inverse (246; 653 with P < 0.01 
and FDR < 0.25) fashion. In addition, genes identified in the regres-
sion analysis included around 90% of the differentially expressed genes 
(DEGs) (27 of 29, FDR < 0.1) found in the comparative analysis 
(Fig. 2A). Consistent with the differential efficiency of the two short 
hairpins, we found a globally stronger transcriptional impact for the 
group of samples targeted by sh2 (fig. S2C) and a milder but never-
theless clearly distinguishable effect of sh1, resulting in particularly 
informative gradient of dosages over the scr control lines.
Particularly noteworthy among the genes that we found correlated 
with BAZ1B levels were (i) crucial regulators of cranial NC, further 
highlighting a convergent BAZ1B dosage–dependent dysregulation 
of the foundational CUL3-centered regulatory axis orchestrating 
NC-mediated craniofacial morphogenesis (30), and (ii) genes asso-
ciated with variation of human facial shape or causative of dysmorphic 
facial features and mild intellectual disability when mutated (Fig. 2B 
and table S1).
Gene Ontology (GO) analysis performed on genes directly 
following BAZ1B levels suggested specific enrichments in biological 
processes such as histone phosphorylation, chromosome localization, 
RNA processing, and splicing. Genes inversely following BAZ1B levels 
were instead enriched in categories particularly relevant for NC and 
NC-derivative functions, such as cell migration and cardiovascular 
and skeletal development (Fig. 2C). By querying the OMIM database, 
we found that several DEGs were associated with genetic disorders 
whose phenotypes include “mental retardation,” “intellectual disability,” 
and/or “facial dysmorphisms” (Fig. 2D), underscoring the pertinence 
of BAZ1B-dependent dysregulation across both the neurocristopathic 
and cognitive axes.
Last, a master regulator analysis identified candidate regulators 
of BAZ1B DEGs, including factors involved in enhancer marking 
[CEBPB, p300, RBBP5, HDAC2 (histone deacetylase 2), KDM1A, 
and TCF12], promoter activation [TBP (TATA box–binding protein), 
TAF1 (TBP-associated factor 1), and POL2 (polymerase 2)], and 
chromatin remodeling (CTCF, RAD21, and YY1) (Fig. 2E and fig. 
S2D), several of which are themselves causative genes of intellectual 
disability syndromes with neurocristopathic involvement, as in the 
case of our recently identified Gabriele–de Vries syndrome caused 
by YY1 haploinsufficiency (31, 32). Chromatin remodeling was in-
deed the most prominently enriched group within the overall domain 
of transcriptional regulation. Two master regulators are particularly 
noteworthy, as they are themselves regulated by BAZ1B dosage. The 
first is EGR1 (FDR < 0.1), which is itself among the genes inversely 
correlated with BAZ1B levels, which is implicated in cranial develop-
ment (in animal models) (33, 34) and whose promoter has been recently 
shown to feature a bivalent state in human embryonic cranial NC 
(23, 35). The second is MXI1, identified as master regulator of genes 
directly following BAZ1B levels (FDR < 0.001), which is itself found 
among the genes inversely correlated with BAZ1B and is itself a regulator 
of BAZ1B, pointing to a cross-talk between the two (fig. S2C). Notably, 
two differentially expressed targets of MXI1, TGFB2 and NFIB, are also 
involved in intellectual disability and craniofacial defects (30, 36, 37).
BAZ1B regulates the NC epigenome  
in a dosage-dependent manner
The transcriptional readout and functional impact of BAZ1B dos-
age (at the level of NC induction and migration) established its role 
as a master controller of the NC. We thus predicted, on the basis of 
its molecular function, that BAZ1B would directly bind to key NC 
target genes and that for some of these, the binding would be dosage 
sensitive. These genes would be, in turn, the most likely direct targets 
to mediate the dosage-dependent transcriptional and functional pheno-
types described above. To test this prediction, we set out to both 
identify BAZ1B direct targets and characterize their promoter and 
enhancer states, so as to mechanistically link their transcriptional 
dysregulation with BAZ1B dosage–dependent chromatin binding. 
Given the absence of chromatin immunoprecipitation (ChIP)–grade 
BAZ1B antibodies, to carry out our ChIP coupled with sequencing 
(ChIP-seq) on scr and KD lines, we first designed a tagging strategy 
to establish, by CRISPR-Cas9 editing, a series of in-frame 3xFLAG 
endogenously tagged BAZ1B alleles in representative iPSCs of the four 
genotypes (Fig. 3A and fig. S3, A and B). These were then differentiated 
to NCSCs (fig. S3C) and subjected to ChIP-seq with anti-FLAG anti-
body, enabling a faithful characterization of BAZ1B genome-wide 
occupancy across dosages (one tagged allele in WBS, two tagged alleles 
in atWBS and CTL, and two tagged alleles in the context of 1.5-fold 
dosages in 7dupASD).
PCA shows a clear separation of the samples by BAZ1B copy num-
ber, with CTL and atWBS samples clustering more closely and WBS 
and 7dupASD samples clustering at opposing positions (Fig. 3B). 
To call NC-specific enhancer regions and promoter-enhancer asso-
ciations, we exploited for chromatin annotation the unprecedented 
resolution afforded by the patients’ cohort with its underlying vari-
ability and proceeded to (i) select chromosomal regions featuring 
H3K4me1 and H3K27ac in at least two individuals; (ii) exclude regions 
marked with H3K4me3 in at least two individuals;(iii) eliminate regions 
bearing a transcription start site (TSS); and (iv) associate each putative 
enhancer to the closest TSS, identifying a total of 30,8470 putative en-
hancer regions. Notably, BAZ1B binds 75% of its targets at their en-
hancer regions (6747 genes), with the remaining 2297 targets bound 
at promoters (Fig. 3C). In addition, 40% of genes expressed in NC 
are bound by BAZ1B, either exclusively at enhancers (27.4%) or exclu-
sively at promoters (3.5%) or at both regions (9%). This highlights 
its pervasiveness within the NC epigenome (Fig. 3C) and is also reflected 
in the key functional enrichments observed for the BAZ1B direct 
targets that are also expressed and that include “axon guidance,” 
“tube development,” “dendrite development,” “outflow tract mor-
phogenesis,” “odontogenesis,” “wound healing,” and “endochondral 
bone morphogenesis” (Fig. 3D). Many of the phenomena captured 
by these GO categories (e.g., odontogenesis and endochondral bone 
morphogenesis) are linked to recent changes in the bone structure 
of modern (versus archaic) humans, with Homo sapiens having charac-
teristically smaller teeth than its extinct relatives.
Last and consistent with the enrichments in NC-defining categories 
uncovered above, the analysis of BAZ1B bound regions revealed 
major convergence with the binding motifs of critical NC regulators, 
including two motifs similar to those of TFAP2A and NEUROG2, 
and one equally associated to TAL1, TCF12, AP4, and ASCL1 
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Fig. 2. BAZ1B KD is responsible for transcriptional alterations in NC-related pathways. (A) Overlap between genes directly or inversely following BAZ1B levels 
identified in the pairwise comparative analysis (scr versus shBAZ1B) and in the regression analysis on BAZ1B-level sensitive genes on iPSC-derived NCSCs (FDR < 0.1). 
(B) Volcano plot reporting DEGs identified in the RNA-seq analysis on iPSC-derived NCSCs [fold change (FC) > 1.25; FDR < 0.1]. (C) Top most specific enrichments for GO 
biological processes among the DEGs in the RNA-seq analysis on iPSC-derived NCSCs. (D) Heat map representing DEGs that are dysregulated in genetic disorders involving 
mental retardation (“Mental”), intellectual disability (“Intellectual”), and/or facial dysmorphisms (“Face”) according to OMIM database classification. cnv, copy number 
variant. (E) Putative regulators of genes that follow BAZ1B levels identified by a master regulator analysis. Regulators were divided in four different groups based on their 
main functions.
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Fig. 3. BAZ1B preferentially binds its targets at their enhancer regions and its KD causes a redistribution of enhancer histone marks. (A) Schematic representation 
of the strategy for CRISPR-Cas9–mediated tagging of endogenous BAZ1B. Briefly, iPSCs from the four genotypes were electroporated with the donor plasmid and the 
Cas9/single-guide RNA ribonucleoprotein complex; clones were selected via hygromycin and PCR, differentiated to NCSCs, and then subjected to ChIP-seq. (B) PCA showing 
the distribution of the four BAZ1B-tagged NCSC lines according to their chromatin profiles. (C) Overlap between genes expressed in our NCSC lines (purple) and genes 
bound by BAZ1B at their enhancer (red) or promoter (blue) regions. (D) Top most specific enrichments for GO biological processes among the genes that are bound by 
BAZ1B and expressed in our NCSC cohort. (E) Most represented BAZ1B DNA binding motifs identified by HOMER show high similarity to neural and NCSC-specific transcription 
factors motifs. (F) BAZ1B differentially bound regions according to its copy number (FDR < 0.1; n = 2). (G) Overlap between genes that are differentially expressed have 
their enhancers differentially marked concordantly (H3K27ac, H3K4me1, and H3K27me3) and are bound by BAZ1B at enhancers.
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(Fig. 3E and text S1A). Thus, BAZ1B binding regions are enriched 
for target sites of major regulators of NC and its neural derivatives 
(38, 39), among which TFAP2A stands out given its core role in neural 
border formation and NC induction and differentiation (40) through 
the binding and stabilization of NC-specific enhancers, in concert 
with NR2F1, NR2F2, and EP300 (41).
Last, we identified 81 regions that are quantitatively bound by 
BAZ1B depending on its copy number (FDR < 0.1) (Fig. 3F), 153 regions 
differentially bound concordantly in WBS and 7dupASD compared 
to control and atWBS samples (FDR < 0.1) (fig. S4A), and 176 and 
25 regions differentially bound preferentially in WBS (fig. S4B) and 
7dupASD (FDR < 0.1) (fig. S4C), respectively.
Given the prominence of its binding to distal regulatory regions, 
we then set out to define the BAZ1B dosage–dependent impact on 
NCSC-specific enhancers by integrating H3K27ac, H3K4me1, H3K27me3, 
and H3K4me3 profiles. We thus performed a regression analysis on 
BAZ1B levels for the distribution of the three histone marks in the 
aforementioned regions and found H3K27ac to be the most affected, 
with 7254 genes differentially acetylated at their enhancers, followed 
by a differential distribution of the H3K4me1 (4048) and H3K27me3 
(2136) marks (fig. S4D). This enabled the overlay of epigenomic 
and transcriptomic profiles, uncovering that among the 1192 DEGs 
identified in the regression RNA-seq analysis, 21.3% (257 of 1192) 
are associated to enhancers that are both bound by BAZ1B and dif-
ferentially H3K27-acetylated in a manner concordant with BAZ1B 
levels (fig. S4E), with a stronger overlap for genes whose expression 
is inversely correlated with BAZ1B levels (160 versus 97). The same 
held for DEGs that have a concordant differential distribution of 
H3K4me1 mark at enhancers (123 versus 55), underscoring the 
consistency of the impact of BAZ1B dosage on distal regulation (fig. 
S4F). In contrast, a lower number of genes (36) showed a concordant 
differential distribution of the H3K27me3 mark and, at the same 
time, were bound by BAZ1B at enhancers (fig. S4G), indicating that 
BAZ1B preferentially affects active chromatin. From this integrative 
analysis, we could thus lastly identify a core set of 30 bona fide direct 
targets of BAZ1B, which are genes whose expression tightly follows 
BAZ1B levels and whose enhancers are bound by BAZ1B and clearly 
differentially modified (Fig. 3G, fig. S4H, and text S1B). Together, 
this first dosage- faithful analysis of BAZ1B occupancy in a diverse 
cohort of human NCSCs establishes its pervasive and mostly distal 
targeting of the NC-specific epigenome, with a preferential activator 
role on the critical transcriptional circuits that define NC fate and 
function.
Intersection with paleogenomic datasets uncovers a key 
evolutionary role for BAZ1B
Mild NC deficits have been put forth as a unifying explanatory 
framework for the defining features of the so-called domestication 
syndrome, with BAZ1B listed among the putative underlying genes 
because of its previously reported role in the NC of model organisms 
(5, 10, 11). The recent observation that its expression is affected by 
domestication-related mobile element insertion methylation in gray 
wolves (12) further supported its role in domestication, offering an 
intriguing parallel to the paleogenomic results that had detected 
BAZ1B within the regions of the modern genome reflective of selec-
tive sweeps and found it enriched for putatively regulatory muta-
tions in AMHs (15).
Having defined the molecular circuits through which BAZ1B 
regulates NC, and since NC changes have been implicated in the 
domestication syndrome (5), since craniofacial differences correlate 
with self-domestication (1), and since 7q11.23 dosage-related cranio-
facial differences in humans relate to the H. sapiens versus Neanderthal 
comparison (fig. S1A), we set out to test the role of BAZ1B dosage in the 
differences between modern and archaic humans. For this, we carried 
out a systematic integrative analysis of the overlaps between our empir-
ically defined BAZ1B dosage–sensitive genes (blue Venn in Fig. 4B) 
and a combination of uniquely informative datasets highlighting 
differences between modern humans and archaics (Neanderthals/
Denisovans) (represented in Fig. 4A by skulls illustrating the more 
“gracile” and “juvenile” profile in AMH relative to Neanderthals visi-
ble in the overall shape of the neurocranium, reduced prognathism, 
brow ridges, and nasal projections) (1, 13–15). Specifically, as shown 
in Fig. 4B, these datasets include (i) genes associated with signals of 
positive selection in the modern branch compared to archaic lineages 
(purple Venn) (13, 14); (ii) genes harboring (nearly) fixed mutations 
in moderns versus archaics (pink Venn); and (iii) genes associated 
with signals of positive selection in the four paradigmatic domesti-
cated species dog, cat, cattle, and horse (1) (orange Venn), to reveal 
statistically significant overlaps between them and genes associated 
with signals of positive selection in the modern branch compared to 
archaic lineages. In turn, the list of genes harboring (nearly) fixed 
mutations in moderns versus archaics contains three classes: (i) genes 
harboring high-frequency changes (15), (ii) genes harboring high- 
frequency missense mutations (red barplot), and (iii) genes enriched 
for high- frequency mutations in regulatory regions (green barplot) 
[data based on (15)] (Fig. 4C). As shown in the barplots, the obviously 
very limited number of high-quality coverage archaic genomes 
available results in a much higher number of nearly fixed changes 
identified in archaics (left/negative side of the plot) versus modern 
humans (right side) (Fig. 4C), setting a comparatively much higher 
threshold for the identification of nearly fixed modern changes.
These analyses are visualized in Fig. 4D (and detailed in tables S2 
and S3) through a matrix that intersects all BAZ1B dosage–dependent 
genes (partitioned in the two categories of directly and inversely 
correlated and ordered across the full range of biological significance 
and regulatory proximity, from simply DEGs to bona fide direct targets) 
with the evolutionary changes underlying domestication and self- 
domestication, yielding the following key insights (color coded for 
degree of overlap and marked for significance in hypergeometric 
tests). First, the most significant pattern was obtains at the inter-
section with the top 10% genes showing an excess of (nearly) fixed 
mutations in the regulatory regions of modern humans compared 
to archaics, across both directly and inversely BAZ1B level–dependent 
genes (table S2). This same category of nearly fixed modern regulatory 
changes is also the only one that returns a statistically significant 
overlap with the most stringent core of BAZ1B dosage–dependent 
targets (i.e., DEGs whose enhancers are both directly bound by BAZ1B 
and differentially marked upon its decrease), demonstrating that BAZ1B 
directly controls, in an exquisitely dosage-dependent manner, this 
coherent and particularly relevant set of genes that underwent regu-
latory changes in human evolution. Second, the overall strongest over-
laps map to the class of genes that are inversely correlated to BAZ1B 
levels, which we found to be strongly and specifically enriched for 
head morphogenesis and NC categories (Fig. 2C), thereby confirming 
craniofacial morphogenesis as the key domain of functionally relevant 
overlap between BAZ1B dosage and (self-) domestication changes 
relevant to the evolution of AMHs. Third, despite the spuriously 
inflated number of apparently fixed mutations in archaics (15), the 
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overall extent of overlap between genes affected by BAZ1B dosage 
and our modern and archaic sets does not reveal significantly more 
hits for archaics. Globally, we found consistently more overlapping 
genes between the BAZ1B targets and the modern human data and 
even no statistically significant overlap for any list of the archaic- 
specific mutations when crossed against genes directly correlated to 
BAZ1B level. We find this noteworthy, given the evidence that the 
Neanderthal face also displays derived characteristics (42) that could 
be the result of modifications of genes that could overlap with those 
highlighted in this work. Last, the (lower) midface emerges as a 
Fig. 4. Exploration of paleogenomic datasets supports a key evolutionary role for BAZ1B and validates the self-domestication hypothesis. (A) Archaic (Neanderthal) 
and modern skulls, illustrating the target domesticated phenotype that was captured by our analysis. Skull images were derived from work under a CC BY-SA 2.0 license 
(https://creativecommons.org/licenses/by-sa/2.0/deed.en) by hairymuseummatt. (B) Overlap between BAZ1B level–sensitive genes and datasets, which bring out differences 
between AMHs and archaics, as well as genes under positive selection in modern humans and domesticates. (C) Barplots showing the occurrence of high-frequency changes, 
missense mutations, and mutations in regulatory regions in genes from the AMH (nearly) fixed mutation dataset (pink Venn in B). (D) Heat map representing the amount 
of overlaps for each list selected from (B). Gene overlaps and detailed list descriptions are reported in table S2. (E) Rendering of a typical WBS face (left) against the background 
of a typical modern face (right). Red segments indicate areas of the lower face where the two faces most sharply depart (nose, philtrum, and lower front of the mandible). 
The lower midface region is most often associated with mutations in genes figuring prominently in our intersections, as discussed in the text and table S3.
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particularly salient area of functionally relevant overlap (as illustrated 
in Fig. 4E and detailed in table S3), given the specific genes that our 
analysis unearthed: (i) COL11A1, one of the few craniofacial genes 
highlighted across domestication studies (dog, house sparrow, and 
pig breeds), which lies in a region of the human genome that resisted 
archaic introgression (13) and is associated with Marshall syndrome; 
(ii) XYLT1, one of the five genes (along with ACAN, SOX9, COL2A1, 
and NFIX) that affect lower and midfacial protrusion, are among the 
top differentially methylated genes compared to archaics and were 
also highlighted in a recent study on regulatory changes that shaped 
the modern human facial and vocal anatomy (tables S1 and S3) (43); 
and (iii) NFIB, which belongs to the same gene family as NFIX and 
shares some of its functions. In sum, the direct and dosage-sensitive 
control by BAZ1B of genes that underwent regulatory changes in 
human evolution and whose altered expression underlies neuro-
cristopathic facial dysmorphisms is consistent with the hypothesis 
of mild neurocristopathy as the mechanistic core selected in the 
self- domestication of the modern human face.
DISCUSSION
As recently reconstructed (3), the idea of human self-domestication 
dates back, at least in terms of scientific record, to Johann Friedrich 
Blumenbach at the onset of the 19th century. Following on his seminal 
account of domestication systematized in Variations of Animals and Plants 
under Domestication (44), Charles Darwin also considered the 
analogy between modern humans and domesticated species in 
The Descent of Man (45), yet his emphasis on controlled breeding 
as a key aspect of domestication led him to frame domestication 
and self-domestication as distinct phenomena and thereby leave 
Blumenbach’s intuition largely undeveloped (46). Since then, the 
possibility that the anatomical and cognitive-behavioral hallmarks 
of AMHs could result from an evolutionary process bearing such 
significant similarities to the domestication of animals as to share 
the same underlying cause has been refined into the full-fledged 
self-domestication hypothesis (1, 2). As recently argued (1, 3), con-
vergent lines of evidence also indicate that self- domestication is tem-
porally aligned with the emergence of AMH, although the process 
may have acquired further momentum with the gradual expansion 
of our species (1, 3). However, despite spurring considerable interest, 
the self-domestication hypothesis has thus far failed to marshal con-
clusive evidence largely because of two factors: (i) the lack of a coherent 
explanation, even at a theoretical level, of what developmental and 
genetic mechanisms could underlie domestication in general and 
(ii) the absence of suitable experimental systems in which those 
mechanisms could be specifically tested in the case of human self- 
domestication. The first problem was tackled by the recent proposition 
of mild NC deficits as a central and unifying functional layer under-
lying domestication (5). This constituted a major conceptual advance, 
particularly because it generated the testable hypothesis of an altered 
NC gene expression program in domesticated species relative to their 
wild-type ancestors. For humans, given the obvious lack of gene ex-
pression data from archaic hominins, we reasoned that this hypothesis 
could be verified by examining the genetic changes between archaic 
and modern humans in light of the gene regulatory networks directly 
inferred from human neurocristopathies. We thus set out to test whether 
specific human neurodevelopmental disorders, carefully selected on 
the basis of both craniofacial and cognitive-behavioral traits relevant 
to domestication, could illuminate the regulatory circuits shaping the 
modern human face and hence be harnessed for an empirical validation 
of the self-domestication hypothesis. Specifically, we reasoned that 
WBS and 7dupASD, through their uniquely informative set of sym-
metrically opposite phenotypes at the level of face morphology 
(fig. S1A) and sociality, constituted a paradigmatic test case to probe 
the heuristic potential of neurodevelopmental disease modeling for 
the experimental understanding of human evolution. The following 
key insights confirm the validity of this approach.
First, we identified the 7q11.23 region BAZ1B gene as a master 
regulator of the modern human face on the basis of a molecular and 
functional dissection in the thus far largest cohort of WBS patient– 
and 7dupASD patient–specific NCSCs and across an exhaustive range 
of BAZ1B dosages. Notably, our cohort also included NCSCs from 
a patient with rare WBS featuring a much milder WBS gestalt and 
harboring an atypical, BAZ1B-sparing deletion that served as a partic-
ularly informative control, as confirmed by the clustering of atypical 
NCSC lines with controls when probed for BAZ1B occupancy. In 
particular, exploiting the fine-grained resolution of BAZ1B dosages 
recapitulated in our cohort, we could couple classical pairwise com-
parisons with a more sophisticated regression analysis on BAZ1B 
levels, thereby revealing major BAZ1B dosage–dependent transcrip-
tional alterations pivoting around clusters of pathways that are crucial 
for NC development and maintenance, as well as for its downstream 
skeletal and cardiac outputs.
Second, we repurposed the versatility of CRISPR-Cas9 to gener-
ate an allelic series of endogenously tagged BAZ1B across 7q11.23 
dosages (including the BAZ1B-sparing atypical patient as uniquely 
relevant control) to define its dosage-dependent genome-wide occu-
pancy. Taking advantage of previous extensive work on the NCSC 
chromatin landscape (41, 47–49), we were able to define a pivotal 
role for BAZ1B in NCSC enhancer regulation, consistent with its 
preferential binding of distal regulatory regions, and to partition its 
dosage-dependent regulation into bona fide direct and indirect targets. 
The overall balance between the numbers of genes up- or down-regulated 
upon BAZ1B KD—together with the greater overlap, sheer size, and 
significance of enrichments in chromatin remodeling categories over 
other domains of transcription regulation—further corroborates the 
inclusion of BAZ1B among the factors acting upstream of enhancer 
and promoter modulations to enable or reinforce rather than specify 
their net outcome. Last, this molecular readout was translated to the 
functional level with the definition of an impairment in both NCSC 
migration and outgrowth from EBs upon decrease in BAZ1B, pro-
viding the first validation of BAZ1B involvement in key functions of 
the developing human NC.
Third, our investigation provides the first experimental evidence 
for the neurocristopathic hypothesis that had been put forth to explain 
the domestication syndrome and had pointed to BAZ1B as one of 
the candidates underlying this syndrome (5). Among the key NC 
hubs affected by BAZ1B dosage, we uncovered three additional critical 
genes—EDN3, MAGOH, and ZEB2—that had also been predicted 
in the same model because they are associated with behavioral changes 
found in domesticates, thereby defining a regulatory hierarchy for 
this coherent set of genes underlying domestication.
Last, the empirical determination of BAZ1B dosage–sensitive 
genes in NC models from AMHs with accentuated domestication- 
relevant traits allowed us to expose, in a functionally relevant manner, 
the genetic differences between modern versus archaic. This brought 
to the fore the significant convergence between BAZ1B-dependent cir-
cuits and genes harboring regulatory changes in the human lineage, 
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reinforcing the notion that regulatory regions contain some of the 
most significant changes relevant for the modern lineage. This is 
also reinforced by the recent identification of AMH-specific hyper-
methylation in the regulatory region of BAZ1B itself (43).
Last, it is noteworthy that genes implicated in NC development 
also play significant roles in the establishment of brain circuits that 
are critical for cognitive processes like language or theory of mind 
prominently affected in 7q11.23 syndromes. Among the genes 
downstream of BAZ1B that we uncovered in this study, FOXP2, 
ROBO1, and ROBO2 have long been implicated in brain wiring pro-
cesses critical for vocal learning in several species (50, 51), including 
humans, and will warrant further mechanistic dissection in light of 
the distinctive linguistic profile of WBS individuals. In conclusion, 
our findings establish the heuristic power of neurodevelopmental dis-
ease modeling for the study of human evolution.
MATERIALS AND METHODS
Human samples
Ethics approvals were reported in the study that established the 
original iPSC cohort (16) and also apply to the additional samples 
included in this study (7dupASD3 and CTL4R).
Fibroblast reprogramming and iPSC culture
WBS1, WBS2, WBS3, WBS4, 7dupASD1, atWBS1, and CTL2 fibroblasts 
were reprogrammed using the mRNA Reprogramming Kit (Stemgent), 
while the 7dupASD2 and CTL1R lines were reprogrammed with the 
microRNA Booster Kit (Stemgent). The CTL3 line was reprogrammed 
by transfection with the STEMCCA polycistronic lentiviral vector 
followed by Cre-mediated excision of the integrated polycistron. 
7dupASD3 and CTL4R fibroblasts were reprogrammed using the 
Simplicon RNA Reprogramming Kit (Millipore).
Before differentiation, iPSC lines were cultured on Matrigel hESC- 
qualified Matrix (BD Biosciences)–coated plates, diluted 1:40 in 
Dulbecco’s minimum essential medium/F-12, and grown in mTeSR 
1 medium (STEMCELL Technologies). They were passaged upon 
treatment with Accutase (Sigma-Aldrich) and then plated in mTeSR 1 
medium supplemented with 5 M Y-27632 (Sigma-Aldrich).
Differentiation
Differentiation into NCSCs was performed as previously described 
(52), with the exception of NCSCs used in the experiment reported 
in Fig. 1 (D and E) (19).
Flow cytometry
NCSCs were detached using Accutase and counted, and 1 × 106 cells 
per experimental condition were fixed in 4% paraformaldehyde and 
then blocked in 10% bovine serum albumin. Cells were incubated 
for 1 hour with primary antibodies conjugated to fluorophores 
(HNK1–fluorescein isothiocyanate and nerve growth factor receptor– 
Alex Fluor 647; BD Biosciences). Analyses were performed on a 
FACSCalibur instrument (BD Biosciences), and data were analyzed 
with FCS express software (Tree Star). Fluorescence-activated cell 
sorting characterization for 7dupASD3 and CTL4R lines is reported 
in fig. S1B; for all the other lines, see (16).
Lentiviral vector production and NCSC transfection
BAZ1B KD was performed using validated pLKO.1 TRC vector 
TRCN0000013338 (referred to as sh1) and TRCN0000013341 (referred 
to as sh2). A pLKO.1 TRC vector containing a scrambled short hairpin 
sequence was used as a negative control.
Second generation lentiviral vectors were produced through cal-
cium phosphate transfection of human embryonic kidney 293T cells 
and ultracentrifugation (2 hours, 20°C, 20,000 rpm).
NCSCs (3 to 4 × 105) were infected upon splitting and then se-
lected by adding puromycin (1 g/ml) to the medium.
RNA extraction, retrotranscription, and real-time qPCR
RNA was extracted using the RNeasy Micro Plus Kit (QIAGEN) 
according to the manufacturer’s instructions. Retrotranscribed cDNA 
was obtained from 0.5 to 1 g of total RNA using the SuperScript 
VILO retrotranscription kit (Thermo Fisher Scientific).
Real-time qPCR was performed on a 7500 Fast Real-Time PCR 
system (Applied Biosystems) using SYBR Green Master Mix (Applied 
Biosystems) as the detecting reagent. A total cDNA amount corre-
sponding to 15 ng of starting RNA was used for each reaction. Each 
sample was analyzed in triplicate and normalized to GAPDH. Relative 
mRNA quantity was calculated by the comparative cycle threshold 
(Ct) method using the formula 2−∆Ct [BAZ1B, CCTCGCAGTA-
AGAAAGCAAAC (forward) and ACTCATCCAGCTCCTTTTGAC 
(reverse); GAPDH, GCACCGTCAAGGCTGAGAAC (forward) and 
AGGGATCTCGCTCCTGGAA (reverse); NR2F1, AGAAGCTCAAG-
GCGCTACAC (forward) and GGGTACTGGCTCCTCACGTA 
(reverse); NR2F2, GCAAGTGGAGAAGCTCAAGG (forward) and 
GCTTTCCACATGGGCTACAT (reverse); TFAP2A, GCCTCTC-
GCTCCTCAGCTCC (forward) and CGTTGGCAGCTTTACGTCTCCC 
(reverse); and SOX9, AGTACCCGCACTTGCACAAC (forward) and 
GTAATCCGGGTGGTCCTTCT (reverse)].
RNA-seq libraries preparation
Library preparation for RNA-seq was performed according to the 
TruSeq Total RNA sample preparation protocol (Illumina), starting 
from 250 ng to 1 g of total RNA. cDNA library quality was assessed 
in an Agilent 2100 Bioanalyzer using the High Sensitivity DNA Kit. 
Libraries were sequenced with the Illumina HiSeq machine at a read 
length of 50–base pair (bp) paired end and a coverage of 35 million 
of reads per sample.
Protein extraction and Western blot
NCSCs were lysed in radioimmunoprecipitation assay buffer [10 mM 
tris (pH 8.0), 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 
140 mM NaCl, and 1 mM EDTA] supplemented with protease in-
hibitor cocktail (Sigma-Aldrich) and 0.5 mM phenylmethylsulfonyl 
fluoride (Sigma-Aldrich) for 1 hour at 4°C.
Protein extracts (30 to 50 g per sample) were supplemented with 
NuPAGE LDS sample buffer (Thermo Fisher Scientific) and 50 mM 
dithiothreitol (Thermo Fisher Scientific) and denatured at 95°C for 
3 min. Then, extracts were run on a precast NuPAGE 4 to 12% bis-tris 
Gel (Thermo Fisher Scientific) in NuPAGE MOPS SDS Running Buffer 
(Thermo Fisher Scientific) and transferred to a 0.45-m nitrocellulose 
membrane (GE Healthcare) for 1 hour at 100 V in a buffer containing 
20% absolute ethanol and 10% 0.25 M tris base and 1.9 M glycine. The 
membranes were blocked in TBST [50 mM tris (pH 7.5), 150 mM NaCl, 
and 0.1% Tween 20] and 5% milk for 1 hour, incubated with primary 
antibodies overnight at 4°C and with secondary antibodies for 1 hour 
at room temperature. Primary [BAZ1B (Abcam) and glyceraldehyde- 
3-phosphate dehydrogenase (GAPDH; Millipore)] and secondary 
antibodies were diluted in TBST and 5% milk. Blots were detected 
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with the ECL Prime Western Blotting Detection Reagents (Sigma- 
Aldrich) and scanned using the ChemiDoc system (Bio-Rad).
Wound-healing assay
Cells (5 × 104 to 7 × 104) were plated in each of the two Matrigel- 
coated wells of silicone culture-inserts (Ibidi) attached to six-well 
culture plates. After 24 hours, the insert was removed, medium was 
changed to remove dead cells, and time lapse was performed for 
24 hours at the rate of one image every 10 min at ×10 magnification; 
each condition was analyzed in duplicate. Images were acquired with 
the BX61 upright microscope equipped with a motorized stage from 
Olympus or the Nikon Eclipse Ti inverted microscope equipped with 
a motorized stage from Nikon and analyzed with ImageJ.
Endogenous BAZ1B tagging via CRISPR-Cas9
iPSCs were pretreated with 10 M rho kinase inhibitor for 4 hours, 
and then 2 × 106 cells were electroporated using the Neon system 
with the Cas9/single-guide RNA ribonucleoprotein complex and the 
donor plasmid (synthesized by GeneArt). The donor plasmid con-
tained three FLAG tags followed by a self-cleaving peptide (P2A) 
and a hygromycin resistance (HygroR). The 3xFLAG-P2A-HygroR 
cassette was flanked by BAZ1B-specific homology arms (5′ HA and 
3′ HA) to promote homologous recombination and then subcloned 
into a bacterial backbone (Fig. 3A).
After 48 hours, iPSC medium was supplemented with hygromy-
cin B (50 g/l), and selection medium was maintained for 15 days. 
Fifteen to 20 clones per iPSC line were then subjected to PCR to (i) 
evaluate the presence of the cassette and the insertion in the correct 
genomic locus and (ii) distinguish heterozygously tagged from homo-
zygously tagged clones (fig. S3A). We could isolate a clone with a 
homozygous integration from the CTL, the atWBS, and the typical 
WBS but not from the 7dupASD line. In the 7dupASD clone, the 
FLAG tag was present in two of three copies, as shown by a digital 
PCR analysis (fig. S3B).
Digital PCR
DNA (60 ng) was amplified in a reaction volume containing the 
following reagents: QuantStudio 3D Digital PCR Master Mix v2 
(Thermo Fisher Scientific), Custom TaqMan Copy Number Assays 
SM 20× FAM labeled (Thermo Fisher Scientific), and TaqMan 
Copy Number Reference Assay 20× (Thermo Fisher Scientific) VIC 
labeled (Thermo Fisher Scientific). The mix was loaded on a chip 
using the QuantStudio 3D Digital PCR Chip Loader. The chips were 
then loaded on the ProFlex PCR System (Thermo Fisher Scientific), 
and data were analyzed using the “QuantStudio 3D AnalysisSuite 
Cloud Software.” The entire process was performed by the qPCR 
Service at Cogentech, Milano [Custom (FLAG) TaqMan Copy Number 
Assays: forward primer, TGGACAGTCCAGAGGACGAA; reverse 
primer, CACCCTTGTCGTCATCGTCTT; and probe, FAMACAGAAGA-
AGGACTACAAAGACG and TaqMan Copy Number Reference 
Assay: TERT (VIC) (catalog number 4403316)].
ChIP coupled with sequencing
Approximately 2 × 105 cells were used (~100 g of chromatin) for 
histone mark IP, and 1 mg of chromatin was used for BAZ1B-FLAG IP. 
Cells were fixed with phosphate-buffered saline, containing 1% formal-
dehyde (Sigma-Aldrich), for 10 min to cross-link proteins and DNA, 
when the reaction was then stopped by adding 125 mM glycine for 
5 min. Cells were lysed with SDS buffer containing 100 mM NaCl, 
50 mM tris-HCl (pH 8.0), 5 mM EDTA (pH 8.0), and 10% SDS, at 
which point chromatin pellets were resuspended in IP buffer contain-
ing 1 volume of SDS buffer and 0.5 volume of Triton dilution buffer 
[100 mM tris-HCl (pH 8.5), 5 mM EDTA (pH 8.0), and 5% Triton 
X-100]. Chromatin was then sonicated using the S220 Focused- 
ultrasonicator (Covaris) to generate <300 bp DNA fragments (for 
histone mark IPs) or the Branson Digital Sonifier to generate 500 to 
800 bp DNA fragments (for BAZ1B-FLAG IP).
Sonicated chromatin was incubated overnight at 4°C with primary 
antibodies [H3K27ac (Abcam), H3K4me1 (Abcam), H3K4me3 (Abcam), 
H3K27me3 (Cell Signaling Technology), and FLAG (Sigma-Aldrich)] and 
then for 3 hours with Dynabeads Protein G (Thermo Fisher Scientific). 
Beads were washed three times with low-salt wash buffer [0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 20 mM tris-HCl (pH 8.0), and 
150 mM NaCl] and once with high-salt wash buffer [0.1% SDS, 1% Triton 
X-100, 2 mM EDTA, 20 mM tris-HCl (pH 8.0), and 500 mM NaCl]. 
Immunocomplexes were eluted in decross-linking buffer (1% SDS 
and 100 mM NaHCO3) at 65°C for 2 hours. DNA was purified using 
QIAquick PCR columns (QIAGEN) and quantified with a Qubit 
dsDNA HS assay kit (Thermo Fisher Scientific). DNA libraries were 
prepared by the sequencing facility at European Institute of Oncol-
ogy according to the protocol described by Blecher-Gonen and col-
leagues (53), and DNA was sequenced on the Illumina HiSeq 2000 
platform. For the FLAG ChIP, samples were run in duplicate.
RNA-seq analysis
RNA-seq data were quantified using Salmon 0.91 to calculate read 
counts and transcripts per million in a transcript- and gene-wise 
fashion, using the quasi-mapping offline algorithm (54) on the GRCh38 
(National Center for Biotechnology Information) database. edgeR 
was used for differential gene expression analysis (DEA), using gen-
eralized linear regression methods, to identify pattern of differential 
expression following two different schemes:
1) A factorial analysis based on the definition of one group of 
scrambled and one group of KD samples to identify genes dys-
regulated similarly across short hairpins characterized by different 
efficiencies.
2) A numerical analysis in which log-normalized [Trimmed Mean 
of M-values (TMM)] BAZ1B levels, as quantified by RNA-seq, was 
used as independent variable.
All analyses were performed dropping individual variations 
(~individual+KD or ~individual+BAZ1B) to account for the genetic 
background of each individual. In particular, this design is expected 
to permit the identification of genes, which change expression level 
upon KD even in situations in which genotype-specific makeups would 
lead BAZ1B-dependent genes to have unique expression levels in 
scramble lines. In the factorial analysis, DEGs were identified and 
characterized by filtering for fold change (FC) > 1.25 and FDR < 0.05 
unless explicitly indicated.
To our knowledge, performing a regression analysis at a gene- 
specific level has never been performed. We were able to do this 
because of the availability of a large set of samples (11 individuals) 
and because of the two short hairpins robustly respectively reducing 
BAZ1B expression levels, respectively by ~40 and ~70% in all indi-
viduals lines. To validate the quality of our numerical differential 
expression analysis, we took advantage of HipSci data (55, 56) and 
iPSCpoweR tools (29). We took 50 of 105 possible combinations of 
13 random individual RNA-seq data from the healthy HipSci cohort, 
representing both sexes and having at least two technical replicates 
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per individual. Unfortunately, HipSci does not contain at least 
13 individuals with three clones per individual. Thus, we performed 
four alternative DEAs with edgeR (table S4) on the 50 different ran-
dom combinations of 13 individuals identified (200 DEAs in total, 
on 22 samples, two clones per individual), using the same model 
matrix used for the regression analysis (~individual+BAZ1B) and 
using BAZ1B levels of scramble and sh2 lines. All analyses identified 
very low number of spurious DEGs (fig. S2E). Thus, we used the 
“Edg2” pipeline (table S4) because it does not discard genes with 
higher variability (Edg2 and Edg4 versus Edg1 and Edg3), and it is 
based on a better suited algorithm (Edg2 versus Edg4). With our 
model matrix, filtering by P < 0.01 (and FDR < 0.25), using Edg2 on a 
random HipSci data, we obtained an average of 93.32 DEGs (on average) 
with a median equal to 43 (table S5). GO enrichments were performed 
using topGO R package version 2.28.0.
Master regulatory analysis was performed via hypergeometric 
test by measuring gene set enrichments in lists of transcription 
factor targets provided by the TFBS tools database (57). Both GO 
and transcription factor enrichment analyses were performed con-
sidering background genes expressed in at least two samples in our 
NCSC cohort.
ChIP-seq analysis
ChIP-seq experiments were analyzed both qualitatively and quantita-
tively. Reads were trimmed with the FASTX-Toolkit (-Q33 -t 20 -l 22), 
aligned with Bowtie 1.0 (-v 2 -m 1) on the Human hg38 reference 
genome, and peaks were called using MACS 2.1.1. H3K4me1, H3K27ac, 
H3K4me3, and H3K27me3 peaks were called with --broad using default 
parameters and q < 0.05.
Qualitative analysis, including intersection and comparison of bed 
files, was performed using BedTools version 2.23.
To define enhancer regions, we intersected those marked by 
H3K4me1 and H3K27ac in at least two samples, discarded re-
gions with H3K4me3 in at least two samples, and discarded regions 
overlapping with TSS. Motif enrichment was performed by using 
HOMER v4.10.
Quantification of reads per region was performed with DeepTools 3.0.2. 
Differential mark deposition was conducted by means of edgeR 3.24.1 
inside R 3.3.3. To define mark deposition following BAZ1B levels, 
we used the same design as for RNA-seq data (~individual+BAZ1B).
To identify BAZ1B bound regions and to avoid losing identifi-
cation of lowly covered regions, we resorted to (i) aggregation of all 
sample aligned reads and (ii) peak calling with MACS2 using –extsize 800 
and q < 0.25. BAZ1B binding coverage was calculated with DeepTools, 
with the same parameters used for histone marks, on the identified 
peak regions. Differentially bound regions were identified with edgeR.
Assembly of archaic and modern human lists
The archaic/modern lists were generated from the material presented 
in (15). We used high-coverage genotypes for three archaic individuals: 
one Denisovan (58), one Neanderthal from the Denisova cave in 
Altai mountains (59), and another Neanderthal from Vindija cave, 
Croatia (60). The data are publicly available at http://cdna.eva.mpg.
de/neandertal/Vindija/VCF/, with the human genome version hg19 
as reference. High-frequency (HF) differences were defined as posi-
tions where more than 90% of present-day humans carry a derived 
allele, while at least the Denisovan and one Neanderthal carry the 
ancestral allele. High-frequency changes in archaics were defined as 
occurring at less than 1% in present-day humans, while at least two 
archaic individuals carry the derived allele. The HF lists used here 
were examined as presented in (15), with the exception of the HF 
lists in regulatory regions, which were extracted from the same dataset 
but not presented as such in the original paper.
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